Metastatic Breast Cancer
From the Journals
PET-CT scans move more women with LABC up to stage IV
The results of a new study comparing the use of PET-CT with conventional methods for staging locally advanced breast cancer has already changed...
Conference Coverage
Multiprong strategy makes clinical trials less White
Only a small percentage of eligible patients participate in clinical trials in the first place, and very few come from racial and ethnic minority...
Conference Coverage
CBSM phone app eases anxiety, depression in cancer patients
Few patients with cancer have access to psycho-oncologic support.
Latest News
T-DXd active in many solid tumors; ‘shift in thinking’
T-DXd is a potential new treatment option for patients with HER2-expressing solid tumors, experts say.
Conference Coverage
Huge underuse of germline testing for cancer patients
Information from germline genetic testing could affect a patient’s cancer care.
Conference Coverage
DEI training gives oncology fellows more confidence
Only 2%-3% of practicing oncologists are Black or Hispanic/Latino, says Yale Cancer Center doctor.
Feature
Drugmakers are abandoning cheap generics, and now U.S. cancer patients can’t get meds
On Nov. 22, three FDA inspectors arrived at the sprawling Intas Pharmaceuticals plant south of Ahmedabad, India, and found hundreds of trash bags...
Conference Coverage
ACS officer provides ASCO highlights: Targeting hidden cancer, AI in oncology
A pair of new studies show that drugs can reduce cancer risk when cells are elusive.
Conference Coverage
New study backs up capecitabine dosing practice in metastatic BC
Study finds similar progression-free and overall survival in 7-day-on/7-day-off schedule, with fewer side effects than 14 days on, 7 days off.
Latest News
In TNBC, repeated biopsies may reveal emergent HER2-low expression
Results could broaden eligibility for treatment with the antibody-drug conjugate trastuzumab deruxtecan.
Feature
Widespread carboplatin, cisplatin shortages: NCCN survey
Only 64% of centers said they are still able to continue treating all current patients receiving carboplatin.